Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cipla Limited
  6. News
  7. Summary
    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 06/21 07:14:08 am
960.15 INR   -0.08%
06/09Indian shares rise on financials boost as COVID-19 cases fall
RE
05/24CIPLA  : to Market Roche's COVID-19 Treatment Drug in India
MT
05/20CIPLA  : Launches COVID-19 Test Kit 'ViraGen' in India
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck taps five Indian drugmakers to expand COVID-19 drug production

04/27/2021 | 07:46am EDT
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey

(Correct typo in company name in paragraph 7)

(Reuters) - Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

The partnership will give the companies license to supply Merck's molnupiravir to India and more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies, Merck said.

Merck said the move is to help address the raging new wave of COVID-19 in India, which has reported more than 300,000 new COVID-19 cases per day over the past six days.

Drugmaker Gilead Sciences Inc on Monday said it will give India at least 450,000 vials of its antiviral drug, remdesivir, and help boost production in the country.

Merck's non-exclusive production pacts for molnupiravir are with companies including Dr.Reddy's Laboratories Ltd and privately held companies Emcure Pharmaceuticals Ltd and Hetero Labs Ltd.

Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalized COVID-19 patients.

Merck has decided to focus on its drugs for COVID-19 after two vaccines failed to generate desired immune responses, prompting it to abandon the program in January.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M. And Shinjini Ganguli)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CIPLA LIMITED -0.08% 960.15 Delayed Quote.17.19%
DR. REDDY'S LABORATORIES LIMITED -0.07% 5284.6 End-of-day quote.1.55%
GILEAD SCIENCES, INC. 1.11% 67.35 Delayed Quote.14.33%
SUN PHARMACEUTICAL INDUSTRIES LTD. 0.43% 671.35 Delayed Quote.12.86%
All news about CIPLA LIMITED
06/09Indian shares rise on financials boost as COVID-19 cases fall
RE
05/24CIPLA  : to Market Roche's COVID-19 Treatment Drug in India
MT
05/20CIPLA  : Launches COVID-19 Test Kit 'ViraGen' in India
MT
05/18CIPLA  : Nomura Adjusts Cipla's Price Target to 1,051 Indian Rupees From 861 Ind..
MT
05/17CIPLA  : Consolidated Profit Jumps in Fiscal Q4; Shares Drop 3%
MT
05/10Indian shares settle up as record high commodity prices lift metal stocks
RE
05/10India COVID cases hold close to record highs as calls widen for national lock..
RE
05/09Eli Lilly signs deals to boost supply of COVID-19 treatment in India
RE
05/06Indian shares pare gains as coronavirus cases surge past 21 mln
RE
05/05CIPLA  : Roche Gets Emergency Use Authorization in India for COVID-19 Treatment ..
MT
More news
Financials
Sales 2021 196 B 2 639 M 2 639 M
Net income 2021 26 116 M 352 M 352 M
Net Debt 2021 1 438 M 19,4 M 19,4 M
P/E ratio 2021 30,1x
Yield 2021 0,41%
Capitalization 774 B 10 436 M 10 441 M
EV / Sales 2021 3,96x
EV / Sales 2022 3,56x
Nbr of Employees 25 845
Free-Float 61,4%
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | CIPLA | INE059A01026 | MarketScreener
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Average target price 998,42 INR
Last Close Price 960,15 INR
Spread / Highest target 21,2%
Spread / Average Target 3,99%
Spread / Lowest Target -18,2%
EPS Revisions
Managers and Directors
NameTitle
Umang Vohra Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Kedar Upadhye Global Chief Financial Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Jaideep A. Gogtay Global Chief Medical Officer
Sector and Competitors